Highlights
- Solid organ transplant (SOT) recipients with a pretransplant cancer history have a significantly increased risk of developing the same type of cancer posttransplant.
- The highest risk association was observed for melanoma, with an incidence rate ratio (IRR) of 10.4.
- Specific cross-cancer associations exist, such as pretransplant kidney cancer increasing the risk of posttransplant thyroid cancer.
- Risk levels for certain cancers (liver, kidney, lung) in SOT recipients were lower than standardized incidence ratios (SIRs) seen in cancer survivors in the general population, suggesting complex interactions between organ disease and immunosuppression.
Background
As the long-term survival of both cancer patients and solid organ transplant (SOT) recipients improves, clinicians are increasingly managing a subset of patients who belong to both categories. It is well-established that SOT recipients face a higher risk of malignancy due to chronic immunosuppression, which impairs immune surveillance. Concurrently, cancer survivors in the general population are known to be at risk for subsequent primary malignancies due to shared genetic predispositions, environmental exposures, or late effects of treatment. However, the specific pattern of cancer risk in SOT recipients who have survived a pre-existing malignancy remains a critical gap in clinical oncology and transplant medicine. Understanding these risks is essential for refining candidate selection, timing of transplantation, and posttransplant surveillance.
Key Content
Methodology and Patient Population
A definitive cohort study published in JAMA Oncology (Tao et al., 2026) analyzed data from the US Scientific Registry of Transplant Recipients linked with 34 population-based cancer registries. This massive dataset covered approximately 92% of the US SOT population from 1995 to 2019, involving 520,424 recipients. The study utilized incidence rate ratios (IRRs) to compare posttransplant cancer risk between those with and without pretransplant cancer, adjusting for age, sex, and the type of organ transplanted.
Site-Specific Cancer Risks
The study identified several high-risk associations where the posttransplant cancer matched the pretransplant type. Seven specific malignancies reached statistical significance after Bonferroni correction:
- Melanoma: Demonstrated the highest risk (IRR, 10.4; 95% CI, 7.43-14.1).
- Urinary Bladder: IRR, 3.72 (95% CI, 2.44-5.39).
- Breast: IRR, 3.71 (95% CI, 3.04-4.48).
- Lung: IRR, 3.65 (95% CI, 2.67-4.86).
- Colorectum: IRR, 2.38 (95% CI, 1.61-3.37).
- Kidney: IRR, 2.34 (95% CI, 1.94-2.79).
- Liver: IRR, 1.73 (95% CI, 1.39-2.14).
Cross-Cancer Risk Associations
Beyond same-site recurrences or new primaries, the research highlighted significant associations between different types of pre- and posttransplant cancers:
- Kidney to Thyroid: Pretransplant kidney cancer was associated with a 2.87-fold increased risk of posttransplant thyroid cancer.
- Liver to Lung/Prostate: Pretransplant liver cancer was associated with increased risks of posttransplant lung (IRR, 1.63) and prostate (IRR, 1.71) cancers.
- Intrahepatic Bile Duct to Pancreas: A strikingly high IRR of 8.56 was observed for pancreatic cancer following a pretransplant bile duct malignancy.
Expert Commentary
The findings from this large-scale analysis suggest that the elevated risk in SOT recipients likely reflects a combination of shared genetic susceptibilities and environmental factors (such as tobacco use in lung and bladder cancers). Interestingly, for liver, kidney, and lung cancers, the IRRs in transplant recipients were actually lower than the SIRs observed in the general cancer survivor population. This paradox may be explained by the fact that for these organs, the pretransplant cancer and the eventual transplant are often related to the same underlying end-stage organ disease (e.g., cirrhosis leading to HCC and then liver transplant).
From a clinical perspective, these data emphasize that a history of cancer should not necessarily preclude transplantation, but it must mandate a highly personalized surveillance plan. The high IRR for melanoma suggests that dermatologic monitoring should be exceptionally rigorous in this subgroup. Furthermore, the association between kidney and thyroid cancers may warrant low-threshold ultrasound screening in kidney cancer survivors undergoing transplant.
Conclusion
This evidence clarifies the landscape of posttransplant malignancy for cancer survivors. While SOT recipients with a pretransplant cancer history are at an increased risk for subsequent malignancies—particularly of the same type—the risk profile varies significantly by cancer site. These findings provide a data-driven foundation for targeted prevention and screening strategies, ensuring that the benefits of transplantation are not undermined by preventable or late-diagnosed secondary cancers. Future research should focus on the impact of specific immunosuppressive regimens on these site-specific risks.
References
- Tao J, Pfeiffer RM, Ahmed S, et al. Cancer Risk in Solid Organ Transplant Recipients With a Pretransplant Cancer History. JAMA Oncol. 2026-03-12. PMID: 41817522.
